Pfiz­er, Sarep­ta and two oth­ers sug­gest Duchenne drug safe­ty is­sues tied to "class ef­fect"

Since the first ex­per­i­men­tal Duchenne gene ther­a­py pro­grams came about, the space has proven rife with safe­ty is­sues and pa­tient deaths in clin­i­cal tri­als. Pfiz­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER